Thomas Hubbard1, Lucy Backholer2, Michael Wiltshire2, Rebecca Cardigan2, Robert A S Ariëns1. 1. Theme Thrombosis, Division of Cardiovascular and Diabetes Research, Multidisciplinary Cardiovascular Research Centre and Leeds Institute for Genetics, Health and Therapeutics, Faculty of Medicine and Health, University of Leeds, Leeds. 2. NHS Blood & Transplant, Cambridge, UK.
Abstract
BACKGROUND: Fresh-frozen plasma (FFP) transfusion carries a risk of viral transmission from donor to recipient. Riboflavin (Mirasol) and amotosalen (Intercept) are two pathogen inactivation (PI) methods that may enhance the safety of FFP for transfusion. Our study investigated the effects of Mirasol and Intercept treatment on fibrin formation and clot structure. STUDY DESIGN AND METHODS: FFP underwent either Mirasol or Intercept treatment, and aliquots were taken before addition of the compound, before illumination (after addition of compound only), and after treatment (addition of compound plus illumination). All samples underwent turbidimetric analysis, lysis analysis, assessment of clot permeation, and analysis by laser scanning confocal microscopy. RESULTS: After treatment, there was a decrease in optical density of the fibrin network for Mirasol and Intercept, lag time to fibrin formation was prolonged for Mirasol and lysis time for Intercept, clot permeability was significantly decreased, and clot density was increased for both. CONCLUSIONS: Our study shows that plasma treated with Mirasol and Intercept produces denser clots consisting of thinner fibers and warrants further studies to evaluate the clinical significance of these structural changes in fibrin clot formation.
BACKGROUND: Fresh-frozen plasma (FFP) transfusion carries a risk of viral transmission from donor to recipient. Riboflavin (Mirasol) and amotosalen (Intercept) are two pathogen inactivation (PI) methods that may enhance the safety of FFP for transfusion. Our study investigated the effects of Mirasol and Intercept treatment on fibrin formation and clot structure. STUDY DESIGN AND METHODS: FFP underwent either Mirasol or Intercept treatment, and aliquots were taken before addition of the compound, before illumination (after addition of compound only), and after treatment (addition of compound plus illumination). All samples underwent turbidimetric analysis, lysis analysis, assessment of clot permeation, and analysis by laser scanning confocal microscopy. RESULTS: After treatment, there was a decrease in optical density of the fibrin network for Mirasol and Intercept, lag time to fibrin formation was prolonged for Mirasol and lysis time for Intercept, clot permeability was significantly decreased, and clot density was increased for both. CONCLUSIONS: Our study shows that plasma treated with Mirasol and Intercept produces denser clots consisting of thinner fibers and warrants further studies to evaluate the clinical significance of these structural changes in fibrin clot formation.
Authors: Chintamani Atreya; Simone Glynn; Michael Busch; Steve Kleinman; Edward Snyder; Sara Rutter; James AuBuchon; Willy Flegel; David Reeve; Dana Devine; Claudia Cohn; Brian Custer; Raymond Goodrich; Richard J Benjamin; Anna Razatos; Jose Cancelas; Stephen Wagner; Michelle Maclean; Monique Gelderman; Andrew Cap; Paul Ness Journal: Transfusion Date: 2019-05-29 Impact factor: 3.157
Authors: Francesco Menichetti; Patrizia Popoli; Maria Puopolo; Stefania Spila Alegiani; Giusy Tiseo; Alessandro Bartoloni; Giuseppe Vittorio De Socio; Sauro Luchi; Pierluigi Blanc; Massimo Puoti; Elena Toschi; Marco Massari; Lucia Palmisano; Giuseppe Marano; Margherita Chiamenti; Laura Martinelli; Silvia Franchi; Carlo Pallotto; Lorenzo Roberto Suardi; Barbara Luciani Pasqua; Marco Merli; Plinio Fabiani; Luca Bertolucci; Beatrice Borchi; Sara Modica; Sara Moneta; Giulia Marchetti; Antonella d'Arminio Monforte; Laura Stoppini; Nadia Ferracchiato; Stefania Piconi; Claudio Fabbri; Enrico Beccastrini; Riccardo Saccardi; Andrea Giacometti; Sara Esperti; Piera Pierotti; Laura Bernini; Claudia Bianco; Sara Benedetti; Alessandra Lanzi; Paolo Bonfanti; Marco Massari; Spartaco Sani; Annalisa Saracino; Antonella Castagna; Luigia Trabace; Maria Lanza; Daniele Focosi; Alessandro Mazzoni; Mauro Pistello; Marco Falcone Journal: JAMA Netw Open Date: 2021-11-01
Authors: Cristina Rosell-Valle; María Martín-López; Fernando Campos; Jesús Chato-Astrain; Rafael Campos-Cuerva; Miguel Alaminos; Mónica Santos González Journal: Front Bioeng Biotechnol Date: 2022-08-23